Scientists may have accidentally discovered a dementia prevention tool that's been available for years.
A shingles vaccine — originally designed to prevent that painful rash you might get from a dormant childhood virus — appears to cut dementia risk by 20%. And in people already diagnosed with dementia, it seems to slow the disease's progression.
The discovery came from a quirk in Welsh health policy. In 2013, Wales offered the vaccine only to people who were exactly 79 — anyone who had already turned 80 was ineligible. This created a near-perfect natural experiment: two groups of people, virtually identical except for a few weeks of age difference, one vaccinated and one not.
When Stanford Medicine researchers tracked these groups for nine years, the results were striking. Among those vaccinated, dementia diagnoses dropped significantly. Even more surprising: people who already had dementia and got the vaccine were far less likely to die from it.
The effect was strongest in women. Whether this comes from stronger immune responses or something else entirely remains unclear. Scientists don't yet know if the vaccine works by suppressing the virus itself or by generally boosting the immune system.
Would you consider getting the shingles vaccine earlier if these findings hold up in clinical trials? Does it change how you think about the connection between viruses and brain health?
For more details, see the full article from Stanford Medicine: https://med.stanford.edu/news/all-news/2025/03/shingles-vaccination-dementia.html
#dementia #vaccines #neuroscience #aging #medicine #science
A shingles vaccine — originally designed to prevent that painful rash you might get from a dormant childhood virus — appears to cut dementia risk by 20%. And in people already diagnosed with dementia, it seems to slow the disease's progression.
The discovery came from a quirk in Welsh health policy. In 2013, Wales offered the vaccine only to people who were exactly 79 — anyone who had already turned 80 was ineligible. This created a near-perfect natural experiment: two groups of people, virtually identical except for a few weeks of age difference, one vaccinated and one not.
When Stanford Medicine researchers tracked these groups for nine years, the results were striking. Among those vaccinated, dementia diagnoses dropped significantly. Even more surprising: people who already had dementia and got the vaccine were far less likely to die from it.
The effect was strongest in women. Whether this comes from stronger immune responses or something else entirely remains unclear. Scientists don't yet know if the vaccine works by suppressing the virus itself or by generally boosting the immune system.
Would you consider getting the shingles vaccine earlier if these findings hold up in clinical trials? Does it change how you think about the connection between viruses and brain health?
For more details, see the full article from Stanford Medicine: https://med.stanford.edu/news/all-news/2025/03/shingles-vaccination-dementia.html
#dementia #vaccines #neuroscience #aging #medicine #science
News Center
For those living with dementia, new study suggests shingles vaccine could slow the disease
A new analysis of a vaccination program in Wales found that the shingles vaccine not only appeared to lower new dementia diagnoses by 20%, it also helped those who already have the disease.
2👍58🕊28⚡25😁25🔥21👀14
🧬 Semaglutide May Slow Biological Aging, First Randomized Human Evidence Suggests
GLP-1 drugs such as semaglutide are already well known for treating obesity and type 2 diabetes. Now, researchers at UC San Diego report the first randomized placebo-controlled evidence that the drug may also slow biological aging — at least as measured by epigenetic aging clocks.
The team analyzed DNA methylation data from a 32-week, double-blind clinical trial involving 108 adults with HIV-associated lipohypertrophy. Participants received either weekly semaglutide injections or placebo. Researchers then used multiple epigenetic clocks — molecular biomarkers that estimate biological aging from chemical modifications to DNA — to evaluate changes in aging rate.
The results, published in Nature Communications, showed that semaglutide significantly slowed several independent measures of biological aging. On the DunedinPACE clock, the pace of aging slowed by about 9%. Significant improvements were also observed with the PCGrimAge clock, which is associated with mortality and age-related disease risk.
A separate 24-week pilot study in people with HIV and fatty liver disease reported that about 42% of participants showed a reduction in DunedinPACE after semaglutide treatment, although that study had no placebo control and should be interpreted cautiously.
In simple terms: epigenetic clocks don’t measure your chronological age. They estimate how quickly the molecular processes associated with aging are progressing. A 9% reduction means these biomarkers changed more slowly during treatment — not that people became 9% younger.
Scientists think several mechanisms may contribute. Semaglutide reduces chronic inflammation, decreases harmful visceral fat, and improves metabolic health — all processes linked to accelerated aging. These changes may influence molecular pathways involved in aging across multiple organ systems.
Key findings:
• ~9% slower pace of aging on the DunedinPACE clock
• Significant improvement in the PCGrimAge mortality-risk clock
• Similar effects across several independent epigenetic aging clocks
• A separate pilot study found ~42% of participants showed slower epigenetic aging after treatment
The study also has important limitations. This was a post hoc exploratory analysis, not a trial originally designed to study aging. Participants all had HIV-associated lipohypertrophy, a condition associated with accelerated biological aging, so the findings cannot yet be generalized to healthy individuals. Most importantly, improvements in epigenetic clocks do not prove that semaglutide extends lifespan or healthspan. Those questions will require much longer clinical studies.
Why it matters: Tens of millions of people already take GLP-1 drugs worldwide. If future studies confirm these findings in broader populations, semaglutide could become one of the first widely used medications shown to influence molecular biomarkers of human aging — extending its impact far beyond weight loss.
📄 https://www.nature.com/articles/s41467-026-72861-3
#Longevity #Semaglutide #GLP1 #Aging #Healthspan
GLP-1 drugs such as semaglutide are already well known for treating obesity and type 2 diabetes. Now, researchers at UC San Diego report the first randomized placebo-controlled evidence that the drug may also slow biological aging — at least as measured by epigenetic aging clocks.
The team analyzed DNA methylation data from a 32-week, double-blind clinical trial involving 108 adults with HIV-associated lipohypertrophy. Participants received either weekly semaglutide injections or placebo. Researchers then used multiple epigenetic clocks — molecular biomarkers that estimate biological aging from chemical modifications to DNA — to evaluate changes in aging rate.
The results, published in Nature Communications, showed that semaglutide significantly slowed several independent measures of biological aging. On the DunedinPACE clock, the pace of aging slowed by about 9%. Significant improvements were also observed with the PCGrimAge clock, which is associated with mortality and age-related disease risk.
A separate 24-week pilot study in people with HIV and fatty liver disease reported that about 42% of participants showed a reduction in DunedinPACE after semaglutide treatment, although that study had no placebo control and should be interpreted cautiously.
In simple terms: epigenetic clocks don’t measure your chronological age. They estimate how quickly the molecular processes associated with aging are progressing. A 9% reduction means these biomarkers changed more slowly during treatment — not that people became 9% younger.
Scientists think several mechanisms may contribute. Semaglutide reduces chronic inflammation, decreases harmful visceral fat, and improves metabolic health — all processes linked to accelerated aging. These changes may influence molecular pathways involved in aging across multiple organ systems.
Key findings:
• ~9% slower pace of aging on the DunedinPACE clock
• Significant improvement in the PCGrimAge mortality-risk clock
• Similar effects across several independent epigenetic aging clocks
• A separate pilot study found ~42% of participants showed slower epigenetic aging after treatment
The study also has important limitations. This was a post hoc exploratory analysis, not a trial originally designed to study aging. Participants all had HIV-associated lipohypertrophy, a condition associated with accelerated biological aging, so the findings cannot yet be generalized to healthy individuals. Most importantly, improvements in epigenetic clocks do not prove that semaglutide extends lifespan or healthspan. Those questions will require much longer clinical studies.
Why it matters: Tens of millions of people already take GLP-1 drugs worldwide. If future studies confirm these findings in broader populations, semaglutide could become one of the first widely used medications shown to influence molecular biomarkers of human aging — extending its impact far beyond weight loss.
📄 https://www.nature.com/articles/s41467-026-72861-3
#Longevity #Semaglutide #GLP1 #Aging #Healthspan
Nature
Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
Nature Communications - Semaglutide is a glucagon-like peptide-1 (GLP-1) with a potential gerotherapeutic role. This post-hoc analysis of a phase 2b trial in adults with HIV associated...
⚡22👀18🔥16😁12👍9🕊7
📊 The U-Curve of Happiness: Why Life Often Gets Better After 50
For decades, the “midlife crisis” was dismissed as little more than a cultural stereotype. But large-scale research suggests it reflects a real statistical pattern.
Economist David Blanchflower (Dartmouth College) analyzed well-being data from 145 countries, controlling for income, education, employment, and marital status. Published in the Journal of Population Economics (2021), the study found a remarkably consistent U-shaped relationship between age and life satisfaction.
Finding Detail
🌍 Scope
145 countries across Europe, Asia, Africa, and the Americas
📉 Lowest point
Life satisfaction typically reaches its minimum in the late 40s (around age 47 in developed countries)
📈 Recovery
Happiness generally rises again through the 50s and 60s, often returning to — or even exceeding — earlier levels
🔁 Consistency
The U-shaped pattern appears across a wide range of cultures and economies, although its strength varies
⚖️ Controls
Results remain after accounting for income, education, marital status, and employment
Why might this happen?
Several explanations have been proposed:
• During midlife, expectations often collide with reality as career growth slows and responsibilities peak — raising children, caring for aging parents, and managing financial pressures.
• Later in life, many people experience fewer competing demands, adjust their expectations, and become more emotionally resilient.
• Neuroscience may offer part of the explanation as well. Separate studies suggest that older adults tend to respond less strongly to negative experiences and naturally focus more on positive ones — although this was not the primary focus of Blanchflower’s research.
One important caveat: this is a population-level trend, not a prediction for any individual. Physical health, close relationships, financial security, and life events remain far more important determinants of happiness than age itself.
Blanchflower’s analysis suggests that the U-shaped pattern of well-being is surprisingly widespread across countries, although its exact shape varies between populations.
📄 Source: Blanchflower D.G. Is happiness U-shaped everywhere? Age and subjective well-being in 145 countries. Journal of Population Economics (2021). DOI: 10.1007/s00148-020-00797-z
#Psychology #Happiness #WellBeing #Science #Aging
For decades, the “midlife crisis” was dismissed as little more than a cultural stereotype. But large-scale research suggests it reflects a real statistical pattern.
Economist David Blanchflower (Dartmouth College) analyzed well-being data from 145 countries, controlling for income, education, employment, and marital status. Published in the Journal of Population Economics (2021), the study found a remarkably consistent U-shaped relationship between age and life satisfaction.
Finding Detail
🌍 Scope
145 countries across Europe, Asia, Africa, and the Americas
📉 Lowest point
Life satisfaction typically reaches its minimum in the late 40s (around age 47 in developed countries)
📈 Recovery
Happiness generally rises again through the 50s and 60s, often returning to — or even exceeding — earlier levels
🔁 Consistency
The U-shaped pattern appears across a wide range of cultures and economies, although its strength varies
⚖️ Controls
Results remain after accounting for income, education, marital status, and employment
Why might this happen?
Several explanations have been proposed:
• During midlife, expectations often collide with reality as career growth slows and responsibilities peak — raising children, caring for aging parents, and managing financial pressures.
• Later in life, many people experience fewer competing demands, adjust their expectations, and become more emotionally resilient.
• Neuroscience may offer part of the explanation as well. Separate studies suggest that older adults tend to respond less strongly to negative experiences and naturally focus more on positive ones — although this was not the primary focus of Blanchflower’s research.
One important caveat: this is a population-level trend, not a prediction for any individual. Physical health, close relationships, financial security, and life events remain far more important determinants of happiness than age itself.
Blanchflower’s analysis suggests that the U-shaped pattern of well-being is surprisingly widespread across countries, although its exact shape varies between populations.
📄 Source: Blanchflower D.G. Is happiness U-shaped everywhere? Age and subjective well-being in 145 countries. Journal of Population Economics (2021). DOI: 10.1007/s00148-020-00797-z
#Psychology #Happiness #WellBeing #Science #Aging
👍32😁13🕊8👀7